Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Olaf Kuhlmann"'
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 152:143-154
Dalcetrapib, a thioester prodrug, undergoes rapid and complete conversion in vivo to its phenothiol metabolite M1 which exerts the targeted pharmacological response in human. In clinical studies, M1 has been quantified together with its dimer and mix
Autor:
Hanna Piper-Lepoutre, Gaurav Tyagi, Eginhard Schick, Olaf Kuhlmann, Thomas Singer, Elisabeth Husar, Maria Solonets
Publikováno v:
Toxicologic Pathology. 45:676-686
Obinutuzumab (GA101, Gazyva™, Gazyvaro®, F. Hoffmann-La Roche AG, Basel, Switzerland) is a humanized, glycoengineered type II antibody targeted against CD20. The preclinical safety evaluation required to support clinical development and marketing
Publikováno v:
Journal of Drug Assessment
Objective The primary objective of this study was to investigate the interaction potential of carmegliptin with P-glycoprotein transporter in vitro and in vivo. A secondary objective was to investigate the safety and tolerability of carmegliptin alon
Autor:
Richard A. Robson, Judith Anzures-Cabrera, Gerhard Arold, Olaf Kuhlmann, David Carlile, Lucy Rowell, Mary Phelan, Darren Bentley
Publikováno v:
Clinical Pharmacokinetics. 52:255-265
Dalcetrapib, a cholesteryl ester transfer protein (CETP) modulator, is a thioester pro-drug that is rapidly hydrolysed to generate a pharmacologically active thiol. The thiol covalently binds to plasma proteins as mixed disulfides, extensively distri
Autor:
Olaf Kuhlmann, Katja Heinig
Publikováno v:
Xenobiotica. 41:430-436
The thioester dalcetrapib is undergoing Phase III clinical evaluation for the prevention and regression of atherosclerosis and the prevention of cardiovascular events through targeting cholesteryl ester transfer protein and increasing high-density li
Publikováno v:
Clinical Therapeutics. 31:586-599
Background: Dalcetrapib (RO4607381/JTT-705) is currently under clinical investigation for the prevention of cardiovascular events. It inhibits the activity of cholesteryl ester transfer protein and has been reported to increase levels of high-density
Publikováno v:
Current Medical Research and Opinion. 25:891-902
The primary objective of this study was to investigate the drug-drug interaction potential of dalcetrapib on drugs metabolized via major cytochrome P450 (CYP) isoforms using both in vitro and clinical approaches. A secondary objective was to investig
Publikováno v:
Pharmaceutical Development and Technology. 12:275-283
The scope of the present article is to study formulation parameters of micellar and of lipid delivery systems on the exposure of a new drug compound A in Wistar rats. A statistical analysis is to be performed a posteriori from a data set of all rat s
Autor:
Lena E. Friberg, Thierry Lavé, Neil Parrott, Olaf Kuhlmann, Anders N. Kristoffersson, Pascale David-Pierson, Elisabet I. Nielsen
Publikováno v:
Pharmaceutical research. 33(5)
Antibiotic dose predictions based on PK/PD indices rely on that the index type and magnitude is insensitive to the pharmacokinetics (PK), the dosing regimen, and bacterial susceptibility. In this work we perform simulations to challenge these assumpt
Autor:
Shunsuke Nagao, Stephen Fowler, Kiyofumi Honda, Kosuke Kawashima, Olaf Kuhlmann, Masayuki Suzuki, Mika Sato, Hitoshi Hagita, Sachiya Ikeda, Mizuki Yamane, Masaki Ishigai, Koji Yamaguchi, Christoph Funk, Yoshinori Aso, Agnès Poirier, Sandrine Simon
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 45(3)
1. The metabolism and drug-drug interaction (DDI) risk of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, were evaluated by in vitro studies using human liver microsomes, human hepatocytes, and recombinant human